Press Release
-
2026/04/24 China Daily
China Daily | Chinese Researchers Debut Breakthrough DNA Repair Tool for Genetic Disorders
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live without the need for lifelong blood transfusions, according to a study published on Wednesday in the journal Nature.
-
2026/04/09 Xinhua Net
In a milestone for genetic medicine, researchers in China have reported the world's first clinical success using a revolutionary "base-editing" technique to treat patients with a severe inherited blood disorder.
-
2025/05/23 China Daily
China Daily | Chinese treatment cures Pakistani girl
A 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor, according to the Children's Hospital of Fudan University in Shanghai.
-
2025/05/21 SHINE
SHINE | Innovative treatment developed in China saves 4-year-old
A 4-year-old Pakistani girl with a serious blood disorder – thalassemia – has been cured by a China-developed innovative gene-editing technology, doctors at the Children's Hospital of Fudan University said on Tuesday.
-
2024/12/10 SHINE
Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder
A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.
-
2023/01/11 PHARMCUBE Colum
As one of the most important technologies in the field of life science in the 21st century, gene editing technology is gradually showing its application potential and vigorous development. According to the data, the global genome editing market is expected to reach $4.3 billion in 2022 and $12.8 billion in 2027. The global genome editing market is expected to grow at a compound annual growth rate of 24.7% in 2022-2027.
-
2022/10/12 Sequoiacap
Following the successful holding of the first science and technology event, Sequoia Talk series Forum medical event recently came to a successful conclusion. In the gene editing session, Mr. Jiang Han, Director & General Manager of Sequoia China, and Dr. Xiaodun Mou, CEO of CorrectSequence Therapeutics (Correctseq), presented a wonderful sharing of cutting-edge gene editing technologies and innovative treatment solutions with the theme of "Turning Knife into Pen, Base Editing Leads Cell and Gene Therapy into Minimally Invasive Era".
-
2022/08/01 SciPhi
Develop Innovative Base Editing System and Nearly 10 Pipelines, 1st Pipeline be IND Ready By 2023
Recently, CorrectSequence Therapeutics (Correctseq), a biotechnology company aims to use their own innovative gene editing system to help people living with serious diseases, announced that transformer Base Editor (tBE) developed independently is authorized by USPTO (United States Patent and Trademark Office) formally and became the Chinese first base editing tool authorized by overseas patents.